Compare SKM & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKM | MEDP |
|---|---|---|
| Founded | 1984 | 1992 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.7B |
| IPO Year | 1999 | 2016 |
| Metric | SKM | MEDP |
|---|---|---|
| Price | $38.43 | $419.80 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $473.17 |
| AVG Volume (30 Days) | ★ 2.0M | 458.7K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 4.28 |
| Revenue | N/A | N/A |
| Revenue This Year | $4.41 | $13.19 |
| Revenue Next Year | $1.85 | $7.75 |
| P/E Ratio | ★ $31.64 | $98.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.66 | $287.17 |
| 52 Week High | $40.49 | $628.92 |
| Indicator | SKM | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 39.94 |
| Support Level | $35.86 | $412.35 |
| Resistance Level | $40.49 | $435.15 |
| Average True Range (ATR) | 1.37 | 11.85 |
| MACD | -0.10 | 0.64 |
| Stochastic Oscillator | 61.99 | 52.74 |
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.